Anavex Life Sciences Corp... (AVXL)

NASDAQ: AVXL · Real-Time Price · USD

9.33

-0.17 (-1.79%)

At close: May 01, 2025, 3:49 PM

Anavex Life Sciences Income Statement

Financials in USD. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1.25K
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-1.25K
Operating Income	n/a	-55.76M	-54.4M	-41.92M	-30.76M	-28.75M	-19.18M	-15.54M	-14.88M
Interest Income	n/a	6.52M	946.99K	26.26K	179.97K	207.28K	255.09K	88.1K	11.32K
Pretax Income	-43M	-47.5M	-47.62M	-37.64M	-26.26M	-26.21M	-17.38M	-13.4M	-14.71M
Net Income	-43M	-47.51M	-47.98M	-37.91M	-26.28M	-26.29M	-17.45M	-13.46M	-14.74M
Selling & General & Admin	11.04M	12.04M	13.07M	9.02M	5.86M	6.85M	5.99M	5.01M	8.33M
Research & Development	41.84M	43.72M	37.92M	32.98M	25.23M	22.26M	13.34M	10.67M	7.25M
Other Expenses	n/a	n/a	3.32M	-54.1K	-149.89K	-298.94K	1.63M	2.02M	151.4K
Operating Expenses	52.88M	55.76M	50.99M	41.95M	30.94M	28.81M	19.18M	15.54M	14.88M
Interest Expense	n/a	964K	946.99K	n/a	n/a	151.13K	n/a	n/a	11.32M
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	n/a	55.76M	50.99M	41.95M	30.94M	28.81M	19.18M	15.54M	14.88M
Income Tax Expense	n/a	7K	358.49K	267.56K	22.66K	82.18K	72.75K	59.61K	29.61K
Shares Outstanding (Basic)	83.47M	79.79M	76.91M	69.8M	58.19M	48.91M	44.66M	40.84M	35.15M
Shares Outstanding (Diluted)	83.47M	79.79M	76.91M	69.8M	58.19M	48.91M	44.66M	40.84M	35.15M
EPS (Basic)	-0.52	-0.6	-0.62	-0.54	-0.45	-0.54	-0.39	-0.33	-0.42
EPS (Diluted)	-0.52	-0.6	-0.62	-0.54	-0.45	-0.54	-0.39	-0.33	-0.42
EBITDA	n/a	-55.76M	-50.94M	n/a	n/a	n/a	n/a	-15.57M	-15.02M
EBIT	n/a	-49.25M	-50.94M	-42.19M	-30.63M	-28.53M	-18.98M	-15.42M	-14.71M
Depreciation & Amortization	n/a	-2.72M	-3.32M	37.45M	26.71M	26.64M	17.5M	1.25K	1.25K